{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:25:37Z","timestamp":1772119537760,"version":"3.50.1"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T00:00:00Z","timestamp":1705363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10147-023-02437-4","type":"journal-article","created":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T03:04:24Z","timestamp":1705374264000},"page":"134-141","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phase II study of S-1 plus docetaxel as first-line treatment for older patients with advanced gastric cancer (OGSG 0902)"],"prefix":"10.1007","volume":"29","author":[{"given":"Tomono","family":"Kawase","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4294-6289","authenticated-orcid":false,"given":"Hiroshi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhiro","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Hoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukinori","family":"Kurokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshio","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taroh","family":"Satoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,1,16]]},"reference":[{"key":"2437_CR1","unstructured":"Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (Vital Statistics of Japan, Ministry of Health, Labour and Welfare) Available at: https:\/\/ ganjoho.jp \/reg_stat \/statistics \/stat\/ summary.html [Last accessed on January 7th, 2023]"},{"issue":"9","key":"2437_CR2","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.6004\/jnccn.2021.0043","volume":"19","author":"D Efrat","year":"2021","unstructured":"Efrat D, Louise CW, Ilene SB et al (2021) NCCN guidelines insights: older adult oncology, version 1.2021. J Natl Compr Canc Netw. 19(9):1006\u20131019","journal-title":"J Natl Compr Canc Netw."},{"issue":"1","key":"2437_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med. 358(1):36\u201346","journal-title":"N Engl J Med."},{"issue":"31","key":"2437_CR4","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24(31):4991\u20134997","journal-title":"J Clin Oncol"},{"issue":"3","key":"2437_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3):215\u2013221","journal-title":"Lancet Oncol"},{"key":"2437_CR6","volume-title":"Japanese gastric cancer treatment guidelines (Ver. 6)","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association (2021) Japanese gastric cancer treatment guidelines (Ver. 6). Kanehara, Tokyo"},{"key":"2437_CR7","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1007\/s10120-018-0797-y","volume":"21","author":"A Makiyama","year":"2018","unstructured":"Makiyama A, Kunieda K, Noguchi M et al (2018) First-line chemotherapy with S-1 alone or S-1 plus cisplatin for elderly patients with advanced gastric cancer: a multicenter propensity score matched study. Gastric Cancer 21:792\u2013801","journal-title":"Gastric Cancer"},{"issue":"1","key":"2437_CR8","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26(1):141\u2013148","journal-title":"Ann Oncol"},{"key":"2437_CR9","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/sj.bjc.6603196","volume":"94","author":"K Yamaguchi","year":"2006","unstructured":"Yamaguchi K, Shimamura T, Hyodo I et al (2006) Phase I\/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803\u20131808","journal-title":"Br J Cancer"},{"key":"2437_CR10","doi-asserted-by":"publisher","first-page":"3402","DOI":"10.1158\/1078-0432.CCR-05-2425","volume":"12","author":"K Yoshida","year":"2006","unstructured":"Yoshida K, Ninomiya M, Takakura N et al (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402\u20133407","journal-title":"Clin Cancer Res"},{"issue":"22","key":"2437_CR11","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1200\/JCO.2006.06.1044","volume":"24","author":"S Kudoh","year":"2006","unstructured":"Kudoh S, Takeda K, Nakagawa K et al (2006) Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 24(22):3657\u20133663","journal-title":"J Clin Oncol"},{"issue":"2","key":"2437_CR12","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","volume":"26","author":"DR Berthold","year":"2008","unstructured":"Berthold DR, Pond GR, Freidele S (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26(2):242\u2013245","journal-title":"J Clin Oncol"},{"issue":"Suppl 1","key":"2437_CR13","first-page":"Abstract 12","volume":"106","author":"30th Annual San Antonio Breast Cancer Symposium","year":"2007","unstructured":"30th Annual San Antonio Breast Cancer Symposium (2007) Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735. Breast Cancer Res Treat 106(Suppl 1):Abstract 12","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"2437_CR14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247","journal-title":"Eur J Cancer"},{"issue":"2","key":"2437_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00432-013-1563-5","volume":"140","author":"W Koizumi","year":"2014","unstructured":"Koizumi W, Kim YH, Fujii M et al (2014) Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START). J Cancer Res Clin Oncol 140(2):319\u2013328","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2437_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1179\/1973947813Y.0000000116","volume":"26","author":"H Imamura","year":"2014","unstructured":"Imamura H, Kishimoto T, Takiuchi H et al (2014) Phase II study of S-1 monotherapy in patients over 75 years of age with advanced gastric cancer (OGSG0404). J Chemother 26(1):57\u201361","journal-title":"J Chemother"},{"issue":"9742","key":"2437_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): phase 3, open-label, randomised controlled trial. Lancet 376(9742):687\u2013697","journal-title":"Lancet"},{"key":"2437_CR18","doi-asserted-by":"publisher","first-page":"2683","DOI":"10.21873\/anticanres.15746","volume":"42","author":"K Chin","year":"2022","unstructured":"Chin K, Takahari D, Kawabata R et al (2022) Initial safety analysis of CapeOx for elderly patients with advanced gastric cancer patients: a phase II trial. Anticancer Res 42:2683\u20132687","journal-title":"Anticancer Res"},{"key":"2437_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.0848","author":"PS Hall","year":"2021","unstructured":"Hall PS, Swinson D, Cairns DA et al (2021) Efficacy of reduced-intensity chemotherapy with oxaliplatin and capecitabine on quality of life and cancer control among older and frail patients with advanced gastroesophageal cancer the go2 phase 3 randomized clinical trial. JAMA Oncol. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0848","journal-title":"JAMA Oncol"},{"key":"2437_CR20","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12885-022-09332-7","volume":"22","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, Zhou A, Sun Y et al (2022) Biweekly oxaliplatin plus S1 for Chinese elderly patients with advanced gastric or gastroesophageal junction cancer as the frst-line therapy: a single-arm, phase 2 study. BMC Cancer 22:253. https:\/\/doi.org\/10.1186\/s12885-022-09332-7","journal-title":"BMC Cancer"},{"key":"2437_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1093\/annonc\/mdj063","volume":"17","author":"A Jatoi","year":"2006","unstructured":"Jatoi A, Murphy BR, Foster NR et al (2006) Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group. Ann Oncol 17:29\u201334","journal-title":"Ann Oncol"},{"key":"2437_CR22","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000305256","volume":"56","author":"HY Luo","year":"2010","unstructured":"Luo HY, Xu RH, Wang F et al (2010) Phase II trial of XELOX as first-line treatment for patients with advanced gastric cancer. Chemotherapy 56:94\u2013100","journal-title":"Chemotherapy"},{"key":"2437_CR23","first-page":"141","volume":"37","author":"YC Kuo","year":"2014","unstructured":"Kuo YC, Liu HT, Lin YL et al (2014) Modified biweekly oxaliplatin and capecitabine for advanced gastric cancer: a retrospective analysis from a medical center. Biomed J 37:141\u2013146","journal-title":"Biomed J"},{"key":"2437_CR24","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00280-014-2407-y","volume":"73","author":"Y Chao","year":"2014","unstructured":"Chao Y, Hsieh JS, Yeh HT et al (2014) A multicenter phase II study of biweekly capecitabine in combination with oxaliplatin as first-line chemotherapy in patients with locally advanced or metastatic gastric cancer. Cancer Chemother Pharmacol 73:799\u2013806","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-023-02437-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-023-02437-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T22:07:04Z","timestamp":1706134024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-023-02437-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,16]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["2437"],"URL":"https:\/\/doi.org\/10.1007\/s10147-023-02437-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2919280\/v1","asserted-by":"object"}]},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,16]]},"assertion":[{"value":"11 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hiroshi Imamura has received honoraria from Taiho Pharmaceutical Co., Ltd. Kazuhiro Nishikawa has received honoraria from Bristol-Myers Squibb Co., Ltd., Daiichi Sankyo, Co., Ltd., EA Pharma Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Ono Pharmaceutical Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Hisato Kawakami has has received honoraria from BMS K.K., ONO Pharmaceutical Co., LTD., Eli Lilly Japan K.K., MSD K.K., and Daiichi Sankyo, Co., Ltd., fees for promotional materials from ONO Pharmaceutical Co., LTD., \u00fcMSD K.K., and Daiichi Sankyo, Co., Ltd., and research funding from BMS K.K., Eisai Co., Ltd., and Kobayashi Pharmaceutical Co. Ltd. Daisuke Sakai has received honoraria from Daiichi Sankyo Co. Ltd., and Chugai Pharmaceutical Co., Ltd., and research funding from Eli Lilly Japan K.K., Daiichi Sankyo Co., Ltd., and Taiho Pharmaceutical Co., Ltd. Yukinori Kurokawa has received lecture fees and research grant from Taiho Pharmaceutical Co., Ltd. Taroh Satoh has received honoraria from ONO Pharmaceutical Co., Yakult Honsha Co., Ltd., Chugai Pharmaceutical Co., Eli Lilly Japan K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., and Taiho Pharmaceutical Co., Ltd., research funding from ONO Pharmaceutical Co., Chugai Pharmaceutical Co., Eli Lilly Japan K.K., Bristol-Myers Squibb Co. Ltd., MSD K.K., Taiho Pharmaceutical Co., Ltd., and Hutch Med Co., Ltd., scholarship donations from Taiho Pharmaceutical Co., Ltd., and endowed chairs from ONO Pharmaceutical Co., Yakult Honsha Co., Ltd., and Chugai Pharmaceutical Co. All the remaining authors have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures in this study were conducted in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants before entry into the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}